| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Non-cleavable Linker
The primary application of Maleimide-DOTA is as a linker in ADC synthesis. The maleimide group targets sulfhydryl groups on antibodies or other proteins, forming stable thioether bonds. The DOTA moiety serves as a chelation site for radioactive metals such as ⁶⁴Cu, ⁶⁸Ga, ¹¹¹In, and ¹⁷⁷Lu, enabling the compound to be used for both therapeutic and diagnostic (theranostic) applications. The compound is classified as a non-cleavable ADC linker, meaning that the conjugate remains intact until the antibody is degraded. |
|---|---|
| ln Vitro |
ADC is made up of an antibody and cytotoxic ADC that are linked together by an ADC linker.
In vitro, Maleimide-DOTA is used for protein conjugation and labeling of radioactive metals. The maleimide group reacts specifically with sulfhydryl groups on proteins under mild conditions (pH 6.5-7.5) to form stable thioether bonds. The DOTA moiety can be labeled with various radiometals for imaging or therapeutic applications. ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker. Maleimide-DOTA serves as a key component in the synthesis of these targeted therapeutic agents. |
| ln Vivo |
No detailed in vivo activity data for Maleimide-DOTA has been published in the available literature. The compound is a research tool used primarily for the synthesis of ADCs and imaging agents. Its in vivo activity would depend on the specific antibody and payload (drug or radioisotope) to which it is conjugated. The non-cleavable nature of the linker means that the conjugate remains intact in circulation until the antibody is degraded.
|
| Enzyme Assay |
The conjugation efficiency of Maleimide-DOTA can be assessed using various analytical techniques. In a typical conjugation reaction, the antibody is first reduced to generate free sulfhydryl groups. Maleimide-DOTA is then added to the reduced antibody at a defined molar ratio. The reaction is incubated at room temperature for a specified period. The degree of conjugation is assessed by MALDI-TOF mass spectrometry or by measuring the chelation of a radioactive metal. The purity of the conjugate is assessed by size exclusion chromatography (SEC) or SDS-PAGE.
|
| Cell Assay |
The cellular activity of Maleimide-DOTA conjugates is assessed in cell-based assays that depend on the specific payload. For ADC applications, the antibody-drug conjugate is added to target cells expressing the appropriate antigen. Cell viability is measured using MTT or CellTiter-Glo assays. The specificity of the conjugate for target cells is assessed by comparing activity against antigen-positive and antigen-negative cell lines. For imaging applications, the radiometal-labeled conjugate is used for PET or SPECT imaging.
|
| Animal Protocol |
No detailed in vivo animal model data for Maleimide-DOTA has been published in the available literature. The compound is a research tool used in the synthesis of ADCs and imaging agents. Its in vivo efficacy would be evaluated in animal models using the specific ADC or imaging agent to which it is conjugated. Typical studies would involve xenograft models for ADC efficacy or biodistribution studies for imaging agents.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data for Maleimide-DOTA has been published in the available literature. The compound has a molecular weight of 526.54 g/mol, a molecular formula of C22H34N6O9, and a LogP of -9.3, indicating high hydrophilicity. It is soluble in water and DMSO at 100 mg/mL. The compound is typically stored as a powder at -20°C and should be protected from moisture and light. Further studies would be needed to characterize the pharmacokinetic properties of Maleimide-DOTA conjugates.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data for Maleimide-DOTA has been published in the available literature. As a research compound used in ADC synthesis, Maleimide-DOTA is not intended for direct therapeutic use. The toxicity of Maleimide-DOTA conjugates would depend on the specific antibody and payload. The compound is typically handled with standard laboratory safety precautions. Comprehensive toxicology studies would be required for any clinical development of Maleimide-DOTA-based conjugates.
|
| Additional Infomation |
Maleimide-DOTA (Maleimido-mono-amide-DOTA) is a non-cleavable bifunctional chelating agent used as a linker in the synthesis of antibody-drug conjugates (ADCs). The maleimide group reacts with sulfhydryl groups on proteins to form stable thioether bonds, while the DOTA moiety chelates radioactive metals for imaging or therapeutic applications. The compound has a molecular weight of 526.54 g/mol, a molecular formula of C22H34N6O9, and a purity of ≥98%. It is soluble in water and DMSO and is typically stored as a powder at -20°C. The CAS number is 1006711-90-5.
|
| Molecular Formula |
C22H34N6O9
|
|---|---|
| Molecular Weight |
526.54
|
| Exact Mass |
526.238
|
| CAS # |
1006711-90-5
|
| PubChem CID |
66893931
|
| Appearance |
White to yellow solid powder
|
| LogP |
-9.3
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
37
|
| Complexity |
846
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C=CC(=O)N1CCNC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1
|
| InChi Key |
AUTDIWAXETZSGJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H34N6O9/c29-17(23-3-4-28-18(30)1-2-19(28)31)13-24-5-7-25(14-20(32)33)9-11-27(16-22(36)37)12-10-26(8-6-24)15-21(34)35/h1-2H,3-16H2,(H,23,29)(H,32,33)(H,34,35)(H,36,37)
|
| Chemical Name |
2-[4,7-bis(carboxymethyl)-10-[2-[2-(2,5-dioxopyrrol-1-yl)ethylamino]-2-oxoethyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 100 mg/mL (189.92 mM)
DMSO : 100 mg/mL (189.92 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (2.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (189.92 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8992 mL | 9.4960 mL | 18.9919 mL | |
| 5 mM | 0.3798 mL | 1.8992 mL | 3.7984 mL | |
| 10 mM | 0.1899 mL | 0.9496 mL | 1.8992 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
